NAPSB

Across TCGA pan-cancer cohorts, NAPSB mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated NAPSB data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher NAPSB mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated NAPSB expression acts as an unfavorable survival marker, although some lineages such as CCRCC and UCEC show a favorable association.

LUAD, LSCC, and CCRCC are the cancer types where NAPSB mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	III,IV	0.409	0.941	.010	13	view →
LSCC	DFS	Quartile	All	0.897	1.000	.008	10	view →
CCRCC	DFS	Tertile	All	1.000	0.608	.025	9	view →
UCEC	DFS	Tertile	All	0.982	0.852	.026	2	view →
PDAC	DFS	Quartile	All	0.663	0.175	.045	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

NAPSB–LUAD (DFS)

Open the LUAD breakdown →